Oncofetal fibronectin is an extracellular matrix protein that is suggested to play an important role in regulating adherence at uterine-placental interfaces. The purpose of the present study was to elucidate a mechanism through which glucocorticoids (GCs) inhibit the synthesis of FN in human placenta as part of their matrix-suppressive action near parturition. We observed that treatment of cytotrophoblasts isolated from human term placentas for 48 h with 10 Ϫ7 mol/L dexamethasone (DEX) down-regulated levels of FN expression to 13-19% of control levels in immunoprecipitation, Northern blotting, and enzyme-linked immunosorbent assay experiments. Conversely, GC treatment increased FN expression in placental fibroblasts to 164 -310% of control levels in Northern blotting and enzyme-linked immunosorbent assay procedures, suggesting that GC-mediated suppression of FN expression is specific to cytotrophoblasts. Results indicated that the DEX-mediated suppression of FN expression in cytotrophoblasts was not mediated through changes in the stability of FN messenger ribonucleic acid (mRNA). Run-on transcription assays using isolated nuclei suggested that GC treatment did not markedly affect transcription of the FN gene in cytotrophoblasts. To test whether the GC-mediated suppression of FN expression was mediated through a protein intermediate, levels of FN mRNA were examined by Northern blotting in cells treated for 48 h with and without 10 Ϫ7 mol/L DEX and cycloheximide (CHX; 125 ng/mL). We observed that CHX treatment increased FN expression in DEX-treated cells to 91% of control values. We noted that whereas the presence of 100 -300 ng/mL CHX reversed the DEX-mediated inhibition of FN mRNA expression in cytotrophoblasts, it did not alter the overall rates of protein synthesis in DEX-treated and control cells. These data suggest that suppression of FN mRNA expression by GC in cytotrophoblasts requires de novo protein synthesis and is mediated through a short lived intermediate, the synthesis of which is inhibited at low concentrations of CHX. Thus, GC-induced protein intermediates may influence uterine-placental adherence by modulating levels of oncofetal FN at sites of uterine-placental contact. (J Clin Endocrinol Metab 83: 632-637, 1998) T HE FIBRONECTINS (FNs) are a family of ubiquitous glycoproteins demonstrated to play an important role in regulating cell adhesion in association with cellular integrin receptors (1, 2). Oncofetal fibronectin (onfFN) is a uniquely glycosylated form of FN that is found in high concentrations in fetal tissue and cancer cell lines, but not in adult tissues (3). Immunohistochemical analysis revealed abundant expression of onfFN in regions of uterine-placental and fetal membrane-decidual contact (4, 5), suggesting that onfFN plays a critical role in regulating cellular adherence at these sites. Primary cultures of cytotrophoblasts isolated from human term placentas were found to synthesize large quantities of FN, and virtually all the FN produced by cytotrophoblasts contained the oncofetal epitope (6, 7).
scription assays using isolated nuclei suggested that GC treatment did not markedly affect transcription of the FN gene in cytotrophoblasts. To test whether the GC-mediated suppression of FN expression was mediated through a protein intermediate, levels of FN mRNA were examined by Northern blotting in cells treated for 48 h with and without 10 Ϫ7 mol/L DEX and cycloheximide (CHX; 125 ng/mL). We observed that CHX treatment increased FN expression in DEX-treated cells to 91% of control values. We noted that whereas the presence of 100 -300 ng/mL CHX reversed the DEX-mediated inhibition of FN mRNA expression in cytotrophoblasts, it did not alter the overall rates of protein synthesis in DEX-treated and control cells. These data suggest that suppression of FN mRNA expression by GC in cytotrophoblasts requires de novo protein synthesis and is mediated through a short lived intermediate, the synthesis of which is inhibited at low concentrations of CHX. Thus, GC-induced protein intermediates may influence uterine-placental adherence by modulating levels of oncofetal FN at sites of uterine-placental contact. (J Clin Endocrinol Metab 83: 632-637, 1998) T HE FIBRONECTINS (FNs) are a family of ubiquitous glycoproteins demonstrated to play an important role in regulating cell adhesion in association with cellular integrin receptors (1, 2) . Oncofetal fibronectin (onfFN) is a uniquely glycosylated form of FN that is found in high concentrations in fetal tissue and cancer cell lines, but not in adult tissues (3) . Immunohistochemical analysis revealed abundant expression of onfFN in regions of uterine-placental and fetal membrane-decidual contact (4, 5) , suggesting that onfFN plays a critical role in regulating cellular adherence at these sites. Primary cultures of cytotrophoblasts isolated from human term placentas were found to synthesize large quantities of FN, and virtually all the FN produced by cytotrophoblasts contained the oncofetal epitope (6, 7) .
Although the etiology of labor is poorly understood, it is clear that parturition is associated with a marked increase in the concentration of glucocorticoid (GC) and CRH in amniotic fluid and maternal and fetal plasma (8 -10) . Recent data demonstrated that plasma levels of biologically active CRH were elevated in women who delivered preterm and were lower in those women who delivered postterm (11) . As the placenta is the major source of plasma CRH during pregnancy (12) , these findings are consistent with the hypothesis that a "placental clock" controls the length of gestation (11) . The finding that GCs increase CRH expression in the placenta and fetal membranes (13) suggests an important role of GC in regulating gestational length.
Previous data obtained in our laboratory demonstrated that GCs specifically and coordinately suppressed the synthesis of extracellular matrix (ECM) proteins in cytotrophoblasts isolated from human placentas (6, 7, 14, 15) . We hypothesize that the parturition-dependent increase in GC may down-regulate ECM protein expression at regions of uterineplacental contact and may be required for separation of the placenta after expulsion of the fetus. The purpose of the present study was to establish cell type-specific patterns and mechanism(s) of GC-mediated suppression of FN expression in human placental cells as a model to elucidate the physiological regulation of ECM protein production at the uterineplacental interface. Using primary cell cultures isolated from term placentas, we report that the chronically expressed, matrix-suppressive action of GC in human placenta is specific to cytotrophoblasts and is mediated through a short lived, cycloheximide (CHX)-sensitive protein intermediate. Elucidation of the mechanism of GC effects on ECM protein expression in the human placenta is of immediate clinical relevance in light of the current recommendation for the antenatal use of GC for enhancement of fetal lung maturity (16) . 
Materials and Methods Materials

Methods
Cell culture. Tissues were obtained from pregnancies with normally grown, singleton fetus. Pregnancies were not complicated by preterm labor, preterm rupture of membranes, or other pathological conditions. The study protocol received approval from the institutional review board committee at New York University Medical Center. Placentas (n ϭ 15) were transported to the laboratory immediately after delivery by cesarean section and were trimmed free of connective tissue and decidua. Cytotrophoblasts were isolated by methodologies developed in our laboratory (6, 7) based on published protocols (17, 18) . Cytotrophoblasts were isolated from villous tissue after trypsin digestion and centrifugation on a continuous Percoll gradient (6, 7) .
Human placental fibroblasts were isolated based on procedures described by Fant and Nanu (19) . Briefly, washed villi were digested for 45 min in a 1:1 mixture of phenol red-free Ham's F-12-DMEM (basal medium) containing 0.1% collagenase and 0.01% DNase. Dispersed cells were filtered through a 160-m pore size stainless steel sieve and seeded in T-75 culture flasks in basal medium supplemented with 10% charcoalstripped calf serum and ITSϩ (i.e. SCS medium). At confluence, the cells were passaged, and second to fourth passage cells were used for experiments. Cytotrophoblasts and fibroblasts were maintained at 37 C in a humidified atmosphere of 5% CO 2 -95% air in SCS medium.
Protein labeling and immunoprecipitation
Levels of protein synthesis in cytotrophoblasts treated with and without DEX and CHX were determined as we have previously described (6) . Briefly, cells were incubated for 4 h in methionine-free SCS medium containing 15 Ci/mL [ 35 S]Protein Labeling Mix, and levels of cellassociated trichloroacetic acid (TCA)-precipitable radioactivity were determined (6 TCA-precipitable counts per min of labeled medium were incubated with a 1:50 dilution of anti-FN antibody and protein G-Sepharose (7). Washing of immune complexes and SDS-PAGE were performed as we previously described (7).
Northern blotting and FN messenger RNA (mRNA) stability
RNA was extracted from cytotrophoblasts using the Ultraspec protocol, a modification of the method of Chomczynski and Sacchi (20) . Approximately 15-25 g total RNA (based on A 260 ) were separated on a 1% agarose gel containing 2.2 mol/L formaldehyde (14) . After transfer of RNA to Zeta-Probe nylon membranes, levels of FN and GAPDH mRNAs were detected using 32 P-labeled cDNA probes as previously described (14) . For FN mRNA stability studies, cells were incubated with and without 10 Ϫ7 mol/L DEX for 48 h. Fresh medium with and without 10 Ϫ7 mol/L DEX containing 1 g/mL actinomycin D was then added for the indicated time. RNA was extracted from cells, and Northern blotting was performed. The zero time point reflects cells harvested before the addition of medium supplemented with actinomycin D.
Run-on transcription assay
Cytotrophoblasts (2 ϫ 10 7 cells/experimental point) maintained 48 h with and without 10 Ϫ7 mol/L DEX were washed with ice-cold phosphate-buffered saline, scraped, and lysed on ice in buffer containing 0.6% Nonidet P-40, 0.15 mol/L NaCl, 10 mmol/L Tris (pH 7. 
Immunoassay for onfFN
Levels of onfFN in culture media were determined by an immunoassay using FDC-6 monoclonal antibody as we previously described (6, 7) . The concentration of cellular protein was quantitated using the D C Protein Assay from Bio-Rad Laboratories (Hercules, CA).
Data analysis
Quantitation of autoradiographic signals and printing of data were carried out using Sigma Scan/Sigma software (St. Louis, MO) as we previously described (21) . Levels of FN expression are expressed as the mean Ϯ sem. Statistical analysis was carried out using Student's t test (SigmaStat software, Jandel, San Rafael, CA).
Results
Effects of GC treatment on FN expression in cytotrophoblasts and fibroblasts
For experiments, cytotrophoblasts and fibroblasts isolated from human term placentas were maintained in SCS medium with and without 10 Ϫ7 mol/L DEX, and levels of FN mRNA and protein were determined using Northern blotting, immunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) procedures. We observed that DEX treatment down-regulated levels of FN mRNA and protein in cytotrophoblasts to 13-19% of control levels ( Fig. 1 and Table 1 ). Conversely, GC treatment increased FN expression in fibroblasts to 164 -310% of control levels, as measured in Northern blotting and ELISA assays (Table 1 ). This suggests that GC-mediated suppression of FN expression is specific to cytotrophoblasts.
FN mRNA stability assay
mRNA stability assays (n ϭ 4) were conducted to elucidate a mechanism of GC-mediated down-regulation of FN expression in cytotrophoblasts. Cells treated for 48 h with and without 10 Ϫ7 mol/L DEX were then maintained for the indicated time with the transcription inhibitor actinomycin D (1 g/mL), and the decay in FN mRNA over time was examined by Northern blotting. The experiment shown in Fig. 2 revealed that DEX treatment did not markedly alter levels of FN mRNA compared to control values, suggesting that the suppressive action of GC on FN expression in cytotrophoblasts was not mediated through changes in message stability.
Run-on transcription assays
Run-on assays using nuclei isolated from cytotrophoblasts were performed to examine the effects of GC treatment on transcription of the FN gene. Levels of FN and GAPDH transcription were 2-to 3-fold greater than those in the negative transcription control condition in which labeled RNA was hybridized to plasmid devoid of FN insert (indicated by PBR in Fig. 3 ). This suggested that cytotrophoblasts expressed relatively low rates of transcription. In four independent experiments, FN gene transcription in DEX-treated cells was 96.7 Ϯ 2.2% of control levels when normalized to Ϫ7 mol/L DEX was then added (time zero), and levels of FN mRNA were estimated by Northern blotting after the indicated period. The intensity of autoradiographic signals is expressed in relative units.
FIG. 3. Effect of DEX on FN gene transcription in cytotrophoblasts.
Cytotrophoblasts were maintained without (control) and with 10 Ϫ7 mol/L DEX for 48 h. Nuclei were then prepared, and transcription assays were conducted as described in Materials and Methods. Labeled RNA was hybridized to a nylon membrane containing plasmids bearing FN and GAPDH cDNAs and a plasmid devoid of insert (PBR). Cytotrophoblasts and fibroblasts isolated from human term placentas were maintained for 3-6 days in SCS medium with and without 10 Ϫ7 M DEX. Levels of FN expression were quantitated in Northern blotting and immunoprecipitation assays following densitometric scanning of autoradiographs. ELISA results were obtained in the onfFN immunoassay, in which media levels of onfFN ranged from 5-11 ng onfFN/g protein and 8 -14 ng/g protein for DEX-treated cytotrophoblasts and fibroblasts respectively. Results for DEXtreated samples in the three assays are presented as a percentage of the control value (mean Ϯ SEM) except for Northern blotting experiments using fibroblasts in which the mean and range obtained in two experiments is shown. The number of independent experiments is shown in parentheses. Statistical analysis by Student's t test indicated that DEX treatment significantly decreased expression of FN in cytotrophoblasts and increased FN expression in fibroblasts. N.D., not determined.
a P Ͻ 0.01. levels of GAPDH transcription, suggesting that GC treatment may not markedly affect rates of FN gene transcription in cytotrophoblasts.
Effect of CHX treatment on levels of FN mRNA in cytotrophoblasts
Studies using CHX, an inhibitor of protein synthesis, were performed to determine whether the GC-mediated suppression of FN expression in cytotrophoblasts was mediated through a protein intermediate. Cells were treated for 48 h with and without 10 Ϫ7 mol/L DEX and CHX at the indicated concentration, and levels of FN mRNA were normalized to levels of GAPDH mRNA after Northern blotting. In the absence of CHX, DEX treatment reduced FN mRNA levels to 18.6% of control values (Fig. 4) . In contrast, in the presence of 125, 250, and 500 ng/mL CHX, the levels of FN mRNA in DEX-treated cells were 115.9%, 106.0%, and 90.0% of control values (i.e. cells maintained with CHX in the absence of DEX), respectively. Lower concentrations of CHX (1-10 ng/mL) were also effective in reversing the GC-mediated inhibition of FN expression (not shown). In five independent experiments in which cells were maintained with and without 100 -125 ng/mL CHX and 10 Ϫ7 mol/L DEX for 48 h, the presence of CHX increased levels of FN mRNA in DEXtreated cells from 18.2 Ϯ 4.4% to 90.8 Ϯ 6.2% of control levels. These values were statistically different at the P Ͻ 0.0001 level. A time course comparing the effect of DEX treatment on levels of FN mRNA in the presence and absence of CHX is presented in Fig. 5 . In the absence of CHX treatment, DEX promoted a reduction in levels of FN mRNA to 6.4% and 7.1% of control levels on days 2 and 4 of culture, respectively. In contrast, in the presence of CHX, the levels of FN mRNA in DEX-treated cells were 86.6%, 98.1%, 88.8%, and 35.3% of control levels on days 1, 2, 3, and 4 of culture, respectively. These results indicated that CHX treatment rapidly reversed the DEX-mediated inhibition of FN expression (i.e. GC treatment no longer down-regulated levels of FN mRNA compared to control values) and suggest that a protein intermediate is involved in GC-mediated suppression of FN expression in cytotrophoblasts.
Effect of CHX treatment on protein synthesis in cytotrophoblasts
Cytotrophoblasts were maintained for 48 h with and without 10 Ϫ7 mol/L DEX and the indicated concentration of CHX (Fig. 6) , and the rate of protein synthesis, expressed as TCAprecipitable radioactivity, was examined after metabolic labeling of cells with 35 S-labeled amino acids. Of note, CHX treatment significantly (P Ͻ 0.0001) reduced the rate of protein synthesis in control and DEX-treated cells only when used at concentrations of 1000 and 3000 ng/mL. This indicated that the DEX-mediated suppression of FN mRNA ex- pression was reversed at a concentration of CHX (i.e. 100 -125 ng/mL) that did not affect the overall level of protein synthesis. In addition, we observed that in the presence and absence of CHX, the rate of protein synthesis was unaffected by DEX treatment (Fig. 6) , suggesting that the effects of DEX in cytotrophoblasts were not due to a coordinate reduction in protein synthesis.
Discussion
The focus of the present investigation was to elucidate a potential mechanism for GC-mediated suppression of FN expression in the human placenta. Previous in vitro studies indicated that cytotrophoblasts of term (6, 7, 22) and first trimester (14) human placentas synthesized large quantities of a uniquely glycosylated FN known as onfFN. Immunohistochemical analysis revealed abundant onfFN at uterineplacental and chorionic-decidual interfaces (4, 5) , suggesting that this molecule plays a critical role in regulating uterineplacental and fetal membrane-decidual adherence across gestation. Work in our laboratory (23) and others (22) suggested that levels of onfFN in human placenta and fetal membranes are established in part through the composite actions of transforming growth factor-␤ and GC. We have found that GC treatment specifically down-regulated the synthesis of FN and other major ECM proteins in cytotrophoblasts and amnion epithelial cells (7, 15) , which is in sharp contrast to the well documented stimulatory effects of GC on FN expression in human fibroblasts and osteosarcoma cells (24) . Our finding that GC treatment also up-regulates FN expression in placental fibroblasts confirms the cytotrophoblast specificity of GC-mediated suppression of FN expression. To the best of our knowledge, no information is available as to the cellular mechanism through which GC down-regulates FN expression.
In the present study we observed that GC suppressed the synthesis of FN mRNA and protein in cytotrophoblasts isolated from human term placentas to approximately 15% of control levels. We also noted that the effects of DEX on FN expression were not mediated through changes in FN mRNA stability. In addition, we observed that GC treatment had little effect on the transcription of the FN gene in cytotrophoblasts as measured in run-on assays. We cannot rule out the possibility that GC may affect FN transcription in cytotrophoblasts, as the levels of transcription in nuclei isolated from control cells were only 2-to 3-fold above background levels. To date, to the best of our knowledge, there are no reported studies of hormone-or growth factor-mediated modulation of promoter/reporter gene activity in transfected primary cultures of cytotrophoblasts isolated from human term placentas. It was recently observed that only extremely small recombinant adenovirus-based systems were effective in transducing cytotrophoblasts and only before their syncytialization in culture (25) .
In the current report we carried out experiments with CHX, an inhibitor of protein synthesis, to determine whether the effects of GC on FN expression were direct or required de novo synthesis of protein. We observed that the presence of 100 ng/mL CHX reversed the GC-mediated suppression of FN mRNA. Our experiments also showed that the effects of CHX were rapid (i.e. they occurred within the first 24 h of treatment) and were observed at concentrations at which the overall level of protein synthesis in cytotrophoblasts was not affected. These results are consistent with the conclusion that suppression of FN expression by GC in cytotrophoblasts requires de novo protein synthesis and is mediated through the action of a short lived intermediate, the synthesis of which is inhibited at low concentrations of CHX.
GC suppression of cytokine gene expression (i.e. its antiinflammatory action) may not be a direct action of the hormone, as it was reversed in the presence of low concentrations of CHX (26) . Recent data suggested that antiinflammatory effects of GCs may be mediated in part through the action of a cytoplasmic inhibitor protein, IB␣ (26, 27) . The results obtained in the present study are consistent with an important role of an intermediate, perhaps an IB␣-like protein, in GC-mediated suppression of FN expression in cytotrophoblasts. However, it must be noted that GC effects in cytotrophoblasts were more chronic in nature (ϳ48 h) than the acute actions of GC (ϳ1-4 h) in the reports (26, 27) discussed above.
There is a well documented elevation in levels of GC in amniotic fluid and maternal and fetal sera in association with parturition whether occurring before or at term (8, 28) . Labor was associated with a reduction in collagen expression in the separation zone of the placenta from the placental bed (29) . Although cytotrophoblast-derived onfFN is present at high concentrations in the zone of placental separation (4, 5) and Nitabuch's fibrin (30), it has not been determined whether labor affects the distribution and/or expression of onfFN at these sites. Our results suggest that a GC-induced protein intermediate may inhibit the synthesis of onfFN by cytotrophoblasts, reduce uterine-placental adherence, and be associated with separation of the placenta from the uterus after expulsion of the fetus. Therefore, it is of prime importance to identify mediators of the matrix-suppressive action of GCs in human placental cytotrophoblasts.
